Evidence map›Paper›PMID 41332843›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Unmasking Hormonal Mechanisms of Hypertension in Obesity.

Stéfanie Parisien-La Salle, Cheng-Hsuan Tsai, Andrew J Newman, Justin M Chan, Julia Milks, Gail Adler, Arnaldo Ferrebus, Isabelle Hanna, Sanan Mahrokhian, Bertram Pitt and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Stéfanie Parisien-La SalleCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Cheng-Hsuan TsaiCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Andrew J NewmanCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Justin M ChanCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Julia MilksCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Gail AdlerCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Arnaldo FerrebusCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Isabelle HannaCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Sanan MahrokhianCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Bertram PittDivision of Cardiology, University of Michigan, School of Medicine, Ann Arbor, Michigan, USA.
Jenifer M BrownCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6647-639X
Anand VaidyaCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0314-9252

Funding

TRAINING PROGRAM IN HYPERTENSIONT32HL007609 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 1985 to 2022
$10.2M
Unrecognized Primary Aldosteronism as a Pathogenic Mechanism for Chronic Kidney Disease in DiabetesR01DK115392 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Anand Vaidya · 2018 to 2026
$6.0M
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in ObesityR01HL153004 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, ANAND · 2020 to 2024
$4.4M
Primary Aldosteronism Subtypes: Pathophysiology and Steroid SignaturesR01HL155834 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TURCU, ADINA F · 2021 to 2025
$3.5M
Cardiac Perfusion, Structure, and Function across the Primary Aldosteronism SpectrumK23HL159279 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Jenifer Michelle Brown · 2022 to 2026
$1.0M
NHLBI NIH HHS K23 HL159279NHLBI NIH HHS R01 HL153004NHLBI NIH HHS R01 HL155834NHLBI NIH HHS T32 HL007609NIDDK NIH HHS R01 DK115392
6 · The paper itself

Abstract

Background: Understanding hormonal mechanisms of obesity-related hypertension may inform the optimal approach to targeted therapy. Objectives: To interrogate hormonal phenotypes of obesity-related hypertension. Methods: 77 participants with obesity and hypertension underwent deep-phenotyping of adrenocortical hormones at baseline and following multiple dynamic maneuvers to suppress and stimulate hormone production, including: the seated saline suppression (SST), oral sodium loading (OSLT) test, dexamethasone suppression test (DST), and ACTH-stimulation (ACTHstim). Participants were classified into 3 aldosteronism phenotypes: (1) primary aldosteronism (PA) phenotype (low renin with non-suppressible aldosterone), low-renin phenotype (low renin and low aldosterone), and renin-dependent aldosteronism (high renin with renin-mediated aldosteronism). The DST was used to evaluate for ACTH-independent hypercortisolism and ACTHstim was used to evaluate ACTH-modulated adrenocortical hormone production. Results: Participants were 55.4 ± 9.4 years, 66.2% women, and had a BMI of 34.8 ± 5.2 kg/m Conclusions: Over 80% of participants with obesity-related hypertension reproducibly exhibited pathologic phenotypes of aldosteronism and/or hypercortisolism. These overlapping hormonal mechanisms reveal the multi-factorial nature of obesity-related hypertension and provide evidence to support aldosterone- and cortisol-directed therapies to treat hypertension in people with obesity.

Indexed as

aldosteronecortisolhypertensionobesityrenin

Identifiers

PMID41332843
PMCPMC12668044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.